HPS Pharmacies wish to give notice that all suppliers are experiencing a supply interruption for all strengths of levothyroxine sodium tablets as follows:
|Product||ARTG||Expected Return Date|
|Eltroxin® 25mcg||206944||Early May 2020*|
|Eltroxin® 50mcg||206960||Early May 2020|
|Eltroxin® 75mcg||206961||Late April 2020|
|Eltroxin® 100mcg||206963||Early April 2020*|
|Eltroxin® 125mcg||206974||Late April 2020*|
|Eltroxin® 200mcg||206954||Early April 2020|
|Eutroxsig® 50mcg||125501||Mid April 2020|
|Eutroxsig® 75mcg||144117||Mid April 2020|
|Eutroxsig® 100mcg||125502||Late April 2020|
|Eutroxsig® 200mcg||125503||Late April-early May 2020|
|Oroxine® 50mcg||125498||End April 2020|
|Oroxine® 75mcg||144108||Late April 2020|
|Oroxine® 100mcg||125499||Mid-late April 2020|
|Oroxine® 200mcg||125500||Mid-late April 2020|
*Warehouses still have limited stock in some states
These supply interruptions are due to an unexpected increase in demand. Eutroxsig® and Oroxine® are not bioequivalent to Eltroxin®. If it is considered necessary to change to or from Eltroxin®, thyroid function should be monitored and the dose adjusted accordingly.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.